Gout | Medical News & Expert Perspectives | HCPLive
The gout condition center is a comprehensive resource for clinical news and expert insights on gout. Read more at HCPLive.
Related Articles
Digestive Disease Week
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care…
Digestive Disease Week
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care…
Ophthalmology Month in Review: April 2025
April sees mixed outcomes in FDA approvals, with promising gene therapies advancing while others face setbacks, highlighting ongoing challenges in ocular treatments.
Pulmonology Month in Review: April 2025
The month in review spotlights new data for COPD and bronchiectasis, as well as new research and conversations around smoking.
FDA Accepts NDA Submission for Oral Semaglutide 25 mg
The FDA accepted the NDA for oral semaglutide 25 mg, a potentially revolutionary daily treatment for weight management and cardiovascular risk reduction.
Azathioprine Effective for Patients with Recalcitrant, Severe Alopecia Areata
In this analysis, investigators highlight the efficacy and safety of azathioprine as a monotherapy for those with recalcitrant and severe alopecia areata.
New National Push to Improve Anaphylaxis Response in Childcare Centers, with Alice Hoyt, MD
HCPLive spoke with Hoyt about the new Early Childhood Anaphylaxis Collaborative, which strives to educate early childcare centers on how to recognize and respond to…
Diabetes Dialogue: Semaglutide for MASH in ESSENCE Trial, With Arun Sanyal, MD
In this episode, hosts explore the promise of semaglutide 2.4 mg in improving liver outcomes for MASH in the Phase 3 ESSENCE trial.
Clinical Perspectives in IBD: An IL-23 Inhibitor with Head-to-Head Results in an Open-Label Crohn’s Disease Study – GI Therapies HCP Live
Evaluate efficacy and show safety results of Risankizumab vs Ustekinumab for the treatment of moderate-to-severe Crohn’s Disease. Explore the study design and outcomes of Risankizumab’s…